3.0-T MR Imaging of Intracoronary Local Delivery of Motexafin Gadolinium into Coronary Artery Walls

Abstract

Purpose:To develop a technique with clinical 3.0-T magnetic resonance (MR) imaging to delineate local contrast agent distribution in coronary artery walls for potential molecular MR imaging-guided local gene or drug therapy of atherosclerotic coronary artery disease. Materials and methods:This animal protocol was approved by the institutional animal care and use committee and was in compliance with the Guide for the Care and Use of Laboratory Animals. For in vitro confirmation, human arterial smooth muscle cells (SMCs) were used to determine capability of SMCs in uptake of motexafin gadolinium (MGd) and its optimal dose. For ex vivo evaluation, a 2-mL mixture of MGd and trypan blue was locally infused into coronary artery walls of six cadaveric pig hearts with MR monitoring and an MR imaging guidewire, surface coils, or both. For in vivo validation, the balloon catheter was placed into coronary arteries of seven living pigs, and the MGd and trypan blue mixture was infused into arterial walls with MR guidance. Signal-to-noise ratio (SNR) and contrast-to-noise ratio (CNR) of coronary artery walls were recorded by using different coils between pre-and postcontrast infusion, with subsequent histologic confirmation. Paired Student t tests were used to compare average SNRs and CNRs of arterial walls before and after contrast agent infusion with different coils. Results:SMCs could take up MGd with the optimal concentration at 150 µmol/L. Average SNR with the MR imaging guidewire and surface coil combination was significantly higher than that with the MR imaging guidewire only or with surface coils only (P , .05), and average SNR and CNR of postinfusion MR imaging was significantly higher than that of preinfusion MR imaging (P , .05). Histologic analysis was used to confirm successful intracoronary infiltration of MGd and trypan blue within coronary artery walls. Conclusion:MR imaging can be used to delineate locally infused contrast agent distribution in coronary artery walls. This establishes groundwork for development of molecular MR imaging-guided intracoronary therapy.q RSNA, 2013 Supplemental material: http://radiology.rsna.org/lookup /suppl

Gliomas: Motexafin Gadolinium-enhanced Molecular MR Imaging and Optical Imaging for Potential Intraoperative Delineation of Tumor Margins

“…Results of previous studies (19)(20)(21)(22) have confirmed that MGd can be internalized exclusively in metabolically active tissues, such as atherosclerotic plaques and different tumors. It also can cross the disrupted blood-brain barrier associated with brain tumors, but it is not detectable in normal brains (18,23,24).…”

“…Qiu et al T1-weighted MR imaging contrast agent, and a red fluorescence emitter (19)(20)(21). In the current study, we attempted to investigate the application of MGd for intraoperative imagingguided complete glioma resection.…”

Molecular Magnetic Resonance Imaging with Contrast Agents for Assessment of Inflammatory Bowel Disease: A Systematic Review

“…Finally, three groups utilized the signal-to-noise ratio (SNR) to analyze the region of interest [10,13,16]. e SNR was calculated by dividing the signal intensity of the samples by the standard deviation of the background noise [17]. Finally, one group utilized the percentage normalized enhancement (%NENH) between the intestine and liver for quantitative evaluation [16].…”

Radiofrequency hyperthermia promotes the therapeutic effects on chemotherapeutic-resistant breast cancer when combined with heat shock protein promoter-controlled HSV-TK gene therapy: Toward imaging-guided interventional gene therapy

“…Recent rapid advances in cancer therapy include image-guided, minimally invasive interventional oncology techniques [ 19 , 20 ]. Previous studies from our group indicated that a combination treatment with local heat-controlled chemotherapy and interventional radiofrequency hyperthermia (RFH) enhances the therapy of various types of malignancies [ 21 – 23 ]. These results encouraged us to develop a new oncologic therapy technique, employing interventional mild RFH for enhanced heat-controlled suicide gene therapy, to solve the problem of multidrug resistance in breast cancer patients.…”